
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Yellow Horn Nut from Xanthoceras sorbifolium contains triterpenes and saponins that cross the blood-brain barrier to provide neuroprotective effects, particularly for cognitive conditions. The seeds are rich in nervonic acid (1.4-3.3%) and linoleic acid (36-39%), supporting nerve cell membrane integrity and cardiovascular health.

Reported Benefits (Provisional)
Origin & History

The Yellow Horn Nut (Xanthoceras sorbifolium) is a unique tree nut native to Northern China, particularly the Yellow River Basin, thriving in arid and semi-arid climates. It is highly valued for its exceptional nutritional profile, including rare fatty acids, making it a significant botanical for cardiovascular and cognitive health.
Research Narrative (Provisional)
Referenced scientific studies support Yellow Horn Nut's benefits for cardiovascular health, cognitive function (especially nervonic acid), and immune support. Research continues to validate its traditional uses and unique nutritional properties.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Monounsaturated fats (oleic acid) - Polyunsaturated fats (linoleic acid) - Nervonic acid - Flavonoids - Vitamin E - Dietary fiber - Magnesium - Potassium - Iron - Zinc - Vitamin B1 (Thiamine) - Vitamin B6 (Pyridoxine) - Calcium
Reported Mechanism (Provisional)
Triterpenes and saponins from Yellow Horn Nut cross the blood-brain barrier to modulate cerebral functions and provide anti-inflammatory, neuroprotective effects targeting Alzheimer's disease pathways. Nervonic acid (C24:1) supports myelin synthesis and nerve cell membrane integrity through fatty acid biosynthesis genes including ACCase, FAD2-2, and DGAT1. Flavonoids like rhoifolin and luteolin-3′-O-glucoside reduce systemic inflammation while supporting intestinal health through metabolite-target-disease networks.
Clinical Narrative (Provisional)
Clinical evidence remains limited, with only one approved treatment in China (FDA Approval Z20040007) using seed extracts for pediatric enuresis due to brain immaturity. This approval confirms that bioactive compounds successfully cross the blood-brain barrier as anti-inflammatory agents in clinical practice. Preclinical studies show promise for triterpenes in Alzheimer's disease and cancer applications, but large-scale human trials with quantified efficacy outcomes are absent. Current evidence is primarily based on traditional use patterns and preliminary bioactive compound research.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







